Toronto - Delayed Quote CAD

Fennec Pharmaceuticals Inc. (FRX.TO)

Compare
8.68 +0.06 (+0.70%)
At close: December 13 at 3:29:53 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
49,348.00
21,252.00
1,535.00
--
170.00
Cost of Revenue
3,200.00
1,259.00
86.00
--
--
Gross Profit
46,148.00
19,993.00
1,449.00
--
--
Operating Expense
44,598.00
33,051.00
24,187.00
17,223.00
18,055.00
Operating Income
1,550.00
-13,058.00
-22,738.00
-17,223.00
-17,885.00
Net Non Operating Interest Income Expense
-2,620.00
-2,953.00
-783.00
-88.00
-324.00
Other Income Expense
-63.00
-34.00
-193.00
-35.00
100.00
Pretax Income
-1,133.00
-16,045.00
-23,714.00
-17,346.00
-18,109.00
Net Income Common Stockholders
-1,133.00
-16,045.00
-23,714.00
-17,346.00
-18,109.00
Diluted NI Available to Com Stockholders
-1,133.00
-16,045.00
-23,714.00
-17,346.00
-18,109.00
Basic EPS
-0.04
-0.60
-0.90
-0.67
-0.76
Diluted EPS
-0.04
-0.60
-0.90
-0.67
-0.76
Basic Average Shares
27,210.00
26,574.00
26,275.00
26,006.00
23,704.00
Diluted Average Shares
27,693.00
26,574.00
26,275.00
26,006.00
23,704.00
Total Operating Income as Reported
1,684.00
-12,771.00
-22,589.00
-17,223.00
-17,885.00
Total Expenses
47,798.00
34,310.00
24,273.00
17,223.00
18,055.00
Net Income from Continuing & Discontinued Operation
-1,133.00
-16,045.00
-23,714.00
-17,346.00
-18,109.00
Normalized Income
-1,070.00
-16,011.00
-23,521.00
-17,311.00
-18,209.00
Interest Income
1,398.00
441.00
195.00
54.00
87.00
Interest Expense
4,018.00
3,394.00
978.00
126.00
9.00
Net Interest Income
-2,620.00
-2,953.00
-783.00
-88.00
-324.00
EBIT
2,885.00
-12,651.00
-22,736.00
-17,220.00
-18,100.00
EBITDA
3,019.00
-12,364.00
-22,587.00
-17,220.00
-18,100.00
Reconciled Cost of Revenue
3,200.00
1,259.00
86.00
--
--
Reconciled Depreciation
134.00
287.00
149.00
16.00
402.00
Net Income from Continuing Operation Net Minority Interest
-1,133.00
-16,045.00
-23,714.00
-17,346.00
-18,109.00
Total Unusual Items Excluding Goodwill
-63.00
-34.00
-193.00
-35.00
100.00
Total Unusual Items
-63.00
-34.00
-193.00
-35.00
100.00
Normalized EBITDA
3,082.00
-12,330.00
-22,394.00
-17,185.00
-18,200.00
12/31/2020 - 6/12/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

8GN.F Cessatech A/S
1.5800
-2.17%
 
J90.F NurExone Biologic Inc.
0.5350
-0.93%
 
VLA.VI Valneva SE
1.7700
-4.27%
 
BBZA.DE BB Biotech AG Ord
37.95
-0.91%
 
TGRP TRON Group Inc.
0.0420
0.00%
 
296.SG CytoDyn Inc
0.1270
+9.48%
 
NRSNW NeuroSense Therapeutics Ltd.
0.2500
-37.50%
 
XRTX.V XORTX Therapeutics Inc.
1.6900
+3.05%
 
FYB.DE Formycon AG
52.70
-0.19%
 
CLVLY Clinuvel Pharmaceuticals Limited
7.91
+1.02%